Results 11 to 20 of about 10,858,974 (235)

Talimogene Laherparepvec (T-VEC): A Review of the Recent Advances in Cancer Therapy [PDF]

open access: yesJournal of Clinical Medicine, 2023
The landscape of melanoma treatment has undergone a dramatic revolution in the past decade. The use of oncolytic viruses (OVs) represents a novel therapeutic approach that can selectively infect and lyse tumor cells and induce local and systemic antitumor immune responses.
Jian Ye, Holly Yin
exaly   +5 more sources

Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma [PDF]

open access: yesCancers, 2021
Direct intralesional injection of specific or even generic agents, has been proposed over the years as cancer immunotherapy, in order to treat cutaneous or subcutaneous metastasis. Such treatments usually induce an effective control of disease in injected lesions, but only occasionally were able to demonstrate a systemic abscopal effect on distant ...
Pier Francesco Ferrucci   +2 more
exaly   +6 more sources

Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells [PDF]

open access: yesFrontiers in Immunology, 2021
T-VEC, a HSV-1 derived oncolytic virus, is approved for the treatment of advanced melanoma. The mechanisms that underly the systemic anti-tumor effect that is seen following intratumoral injection have not yet been studied but are likely to be mediated by myeloid dendritic cells (myDC) that initiate an adaptive immune response.
Julia Katharina Schwarze   +2 more
exaly   +10 more sources

False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC). [PDF]

open access: yesJ Surg Oncol, 2021
AbstractTalimogene laherparepvec (T‐VEC) is a genetically modified herpes simplex virus‐1‐based oncolytic immunotherapy and has been approved for the local treatment of unresectable (stage IIIB/C and IVM1a) cutaneous melanoma. During T‐VEC treatment, tumor response is often evaluated using [18F]2‐fluoro‐2‐deoxy‐ d‐glucose(FDG) positron emission ...
Mulder EEAP   +12 more
europepmc   +8 more sources

Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Melanoma [PDF]

open access: yesImmunotherapy, 2015
Melanoma often spreads to cutaneous or subcutaneous sites that are amenable to direct, intralesional injection. As such, developing effective injectable agents has been of considerable interest. Talimogene laherperepvec (T-VEC) is an injectable modified oncolytic herpes virus being developed for the treatment of advanced melanoma.
Mark C. Kelley   +2 more
exaly   +5 more sources

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. [PDF]

open access: yesJ Immunother Cancer, 2016
With the recent regulatory approval of Talimogene laherparepvec (T-VEC) for the treatment of advanced of melanoma in the United States, Europe and Australia, oncolytic virus immunotherapy has earned its place in the clinic. However, the adoption of T-VEC by the U.S.
Rehman H, Silk AW, Kane MP, Kaufman HL.
europepmc   +7 more sources

Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. [PDF]

open access: yesJ Immunother Cancer, 2017
Immunotherapy plays a key role in the treatment of metastatic melanoma. Patients with autoimmune conditions and/or on immunosuppressive therapy due to orthotropic transplants, however, are systematically excluded from clinical trials. Talimogene laherparepvec (T-VEC) is the first oncolytic virus to be approved by the FDA for cancer therapy.
Schvartsman G   +4 more
europepmc   +6 more sources

Case report: Therapeutic potential of T-VEC in combination with MEK inhibitors in melanoma patients with NRAS mutation. [PDF]

open access: yesFront Oncol, 2023
Mutations in the NRAS gene are common alterations in malignant melanoma. However, there are no specific treatment options approved for NRAS-mutated melanoma patients besides immune checkpoint inhibition. Since preclinical data suggests a synergistic effect of a MEK inhibitor (MEKi) and the oncolytic virus talimogene laherparepvec (T-VEC), we have ...
Simon SCS, Müller V, Utikal JS.
europepmc   +4 more sources

Inflammatory Colitis after Treatment of Melanoma with Talimogene Laherparepvec (T-VEC) [PDF]

open access: yesJournal of Immunotherapy and Precision Oncology, 2018
Abstract Talimogene laherparepvec (T-VEC) is an intralesional oncolytic viral therapy for the treatment of recurrent, unresectable cutaneous, subcutaneous, and nodal melanoma. It is thought to work through direct tumor oncolysis and by eliciting a tumor-specific systemic immune response.
Jennifer Gardner   +3 more
openaire   +3 more sources

Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review. [PDF]

open access: yesCurr Oncol Rep
Abstract Purpose of review As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse. Recent findings While surgery remains a mainstay in staging and treatment of locoregional ...
Kalsi S   +5 more
europepmc   +3 more sources

Home - About - Disclaimer - Privacy